<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C7B2F79C-C794-4597-898F-93292A2B77A3"><gtr:id>C7B2F79C-C794-4597-898F-93292A2B77A3</gtr:id><gtr:name>Fit Biotech Oy</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C7B2F79C-C794-4597-898F-93292A2B77A3"><gtr:id>C7B2F79C-C794-4597-898F-93292A2B77A3</gtr:id><gtr:name>Fit Biotech Oy</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A5EEF8B8-F133-43A5-8E49-CA03803B21B5"><gtr:id>A5EEF8B8-F133-43A5-8E49-CA03803B21B5</gtr:id><gtr:firstName>Frances</gtr:firstName><gtr:otherNames>M</gtr:otherNames><gtr:surname>Gotch</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/062FDFDF-EE07-461D-A1D1-86BFFD0A8A9D"><gtr:id>062FDFDF-EE07-461D-A1D1-86BFFD0A8A9D</gtr:id><gtr:firstName>Nesrina</gtr:firstName><gtr:surname>Imami</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0501957"><gtr:id>418F762D-A9D4-4677-B1AD-8D86808EEEC2</gtr:id><gtr:title>Novel interventions in HIV-1 infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501957</gtr:grantReference><gtr:abstractText>Currently more than 40 million persons worldwide are living with HIV-1. Most of these persons are too impoverished to afford antiretroviral drug treatment (ART), which, in any case, does not cure HIV-1 disease, has many side effects, and must be taken for a lifetime to be fully effective. It is obvious that more user-friendly, less costly, and short-term rather than lifelong treatments are needed. Although viral eradication from the infected host must remain the ultimate goal, enabling the host to co-exist with the virus may be a more realistic immediate goal. Thus we feel it is time to move some of our scientific knowledge from the bench to the bedside. We and others have clearly shown that a few HIV-1+ people can survive for many years without drug intervention, and that these people do not lose the HIV-1-specific cellular immune responses which are important in controlling viral growth. Such long-term non-progressors (LTNP) have low viral loads and low transmission potential. If we could turn chronic progressors into long-term non-progressors we would reduce the economic and clinical burden of ART and have a profound effect on the future pandemic. We propose to enrol 30 HIV-1+ volunteers who have been on ART for some time, with low viral loads, and with CD4 T-cell counts which have risen to 400 or more. We have already shown that such individuals do not make effective immune responses to HIV-1, although immune responses to other bugs (such as CMV) may be restored. If such people stop taking ART viral loads rebound and CD4 T-cell counts rapidly drop. We will divide the treatment groups into 3 arms in an immune based therapy trial as follows: Arm 1. DNA vaccine containing many ?pieces? of HIV-1; followed by a cocktail of safe immunomodulatory drugs to help the vaccine responses survive; followed by two boosts with DNA vaccine. Arm 2. DNA vaccine (as in arm 1) given three times without immunomodulatory drugs. Arm 3. The cocktail of immunomodulatory drugs alone. ill compare HIV-1-specific immune responses between different arms and to those observed in LTNPs. In the future we may feel able to stop ART and compare viral rebounds.</gtr:abstractText><gtr:technicalSummary>A series of rational, novel, immune-based therapeutic (IBT) interventions in HIV-1 infection are proposed, each with the potential to introduce those kinds of responses seen in long-term non-progressor (LTNP) patients into chronically infected HIV-1 patients on successful antiretroviral therapy (ART). Our aim is to deliver immunotherapy which will reverse the anergic immunological state seen in ART-treated chronic progressors, and improve long-term HIV-1-specific cellular functional memory responses, resulting in greater virological control and slower disease progression. Such effective immune-based therapy may eventually allow discontinuation, or at least interruption, of ART for prolonged periods of time, thus reducing the economic and clinical burden of ART.

We propose a five armed, open-label, randomised trial of two novel vaccine antigens (HIV-1 multigene ? nef, rev, tat, gag, RT, env DNA; and new generation Remune CpG), which will be administered +/- cytokines (IL-2 and GM-CSF) and recombinant growth hormone (rGH). The trial is designed to ensure 80% power to show significant changes (p=0.05). We suggest that sustained responses may be induced using a rationalised immunotherapy regimen where: 
1. Patients are treated with ART before CD4 T-cell counts fall below 200 cells/ul blood.
2. Reconstitution of CD4 T cells is allowed to a level equal or above 400 cells/ul blood.
3. Specific cellular responses and/or innate responses are induced or reintroduced by priming with vaccines representing a broad spectrum of antigens with novel adjuvants.
4. Survival of vaccine responses is increased through the administration of cytokines/hormones during the antigen-specific T-cell contraction phase of the immune response (between 8 and 15 days post-vaccination).
5. Memory responses are boosted with further immunisation.

Novel, meaningful, validated assays with standardised criteria and procedures will enable us to evaluate a substantial number of parameters for antigen-specific T cells, dendritic cells and NK cells, including absolute frequencies, phenotypical subpopulations, and functional capacities (including cytokine secretion, degranulation, proliferation, cytotoxicity).

Immunological endpoints during the IBT trial will be changes in breadth and/or strength of specific cellular responses, and reduction of viral reservoirs compared to baseline values (before IBT). Comparisons will be drawn with similar responses in LTNP patients. Evaluations of the complexity and amplitude of immunological response after immunization is a challenge for investigators trying to define optimal technologies and methodologies, and to define vaccine and infection-induced T-cell responses. Therefore, all options will be equally considered for the evaluation of potential immunological responses.</gtr:technicalSummary><gtr:fund><gtr:end>2010-10-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-10-02</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>925735</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fit Biotech Oy</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>Vaccine provider</gtr:description><gtr:id>695C0AB5-3E62-4A34-BD2F-6DD9D6737F9F</gtr:id><gtr:impact>Vaccine; The project would not be possible without the vaccine!</gtr:impact><gtr:outcomeId>C6ACEB7C599-1</gtr:outcomeId><gtr:partnerContribution>The project would not be possible without the vaccine!</gtr:partnerContribution><gtr:piContribution>The collaboration between FIT Biotech and Imperial College has enabled the trial to go forward after many difficulties with other vaccine manufacturers</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>interviews</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>D98757BE-A528-41C0-846F-01943F4564BF</gtr:id><gtr:impact>interviews with journalists, mostly by phone

None</gtr:impact><gtr:outcomeId>1DE09220FCF</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008,2009,2010,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>local funding</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>Imperial College London</gtr:fundingOrg><gtr:id>16B4A5D4-FB13-4B01-A3AD-493F5F27BB14</gtr:id><gtr:outcomeId>0585DD9A1D10</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>wellcome trust fellowship</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>22FB41A4-269B-48E4-B320-7BA0FBB2EB59</gtr:id><gtr:outcomeId>C1FF128529B0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7C307BCC-3BB6-4CA7-BFFA-14F1A46599B4</gtr:id><gtr:title>Rapid qualitative and quantitative analysis of T-cell responses in HIV-1-infected individuals receiving successful HAART and HIV-1 sero-negative controls: concomitant assessment of perforin, IFN-gamma and IL-4 secretion.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8b699e4e78b665e39d0530646ba489f"><gtr:id>d8b699e4e78b665e39d0530646ba489f</gtr:id><gtr:otherNames>Burton CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>2E84919A4A9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99D26FBD-3062-4DA1-AF59-4A5D8F00ABB5</gtr:id><gtr:title>Cutaneous human papillomavirus-related immune reconstitution-associated disease in human immunodeficiency virus: an under-recognized phenomenon.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3b31c9cc92ded6ab677df554f2dc341"><gtr:id>c3b31c9cc92ded6ab677df554f2dc341</gtr:id><gtr:otherNames>Meys R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>VDKGjNowKZJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10E90D92-DA60-4CB7-8316-1B687C1C7AF5</gtr:id><gtr:title>CCR2/64I mutation detection in a HIV-1-positive patient with slow CD4 T-cell decline and delay in disease progression.</gtr:title><gtr:parentPublicationTitle>International journal of STD &amp; AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8b699e4e78b665e39d0530646ba489f"><gtr:id>d8b699e4e78b665e39d0530646ba489f</gtr:id><gtr:otherNames>Burton CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0956-4624</gtr:issn><gtr:outcomeId>E13D347241F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01F5FB25-EE9B-4B26-8AC4-18C1AC6C4ABB</gtr:id><gtr:title>Ex-vivo recognition of late-lytic CD8 epitopes specific for Kaposi's sarcoma-associated herpesvirus (KSHV) by HIV/KSHV-coinfected individuals.</gtr:title><gtr:parentPublicationTitle>Viral immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0988cb57bc8067ff3f49d02de14bc7bd"><gtr:id>0988cb57bc8067ff3f49d02de14bc7bd</gtr:id><gtr:otherNames>Robey RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0882-8245</gtr:issn><gtr:outcomeId>PDvY1WSjiVg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F26138F-6FEE-4F4B-B56D-904CA743E8AE</gtr:id><gtr:title>Myometrial cytokines and their role in the onset of labour.</gtr:title><gtr:parentPublicationTitle>The Journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc7f28d8968943cb0b443ac3a4fdfe82"><gtr:id>bc7f28d8968943cb0b443ac3a4fdfe82</gtr:id><gtr:otherNames>Sivarajasingam SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-0795</gtr:issn><gtr:outcomeId>5a34f469ba6076.45355265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5477C08-83E4-476D-9FB1-2DF8BA7EC98D</gtr:id><gtr:title>Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02392ae529e06175e91d6ba0c608972d"><gtr:id>02392ae529e06175e91d6ba0c608972d</gtr:id><gtr:otherNames>Buisson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>F1A304EAE7B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEF96491-9D2C-4B52-B036-A4C9D94DAE94</gtr:id><gtr:title>An anniversary without celebration?</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e086ef237c69f5d7e2326de60af7d86a"><gtr:id>e086ef237c69f5d7e2326de60af7d86a</gtr:id><gtr:otherNames>Imami N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>733E9B29CA8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>964256F5-9317-4F4E-A073-A8C12EA97252</gtr:id><gtr:title>Novel approach to recognition of predicted HIV-1 Gag B3501-restricted CD8 T-cell epitopes by HLA-B3501(+) patients: confirmation by quantitative ELISpot analyses and characterisation using multimers.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f987db5d930428320510421f29a35f30"><gtr:id>f987db5d930428320510421f29a35f30</gtr:id><gtr:otherNames>Westrop SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>doi_55f983983c87819c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4E190C6-DE7F-4F63-9406-0F05D2D20657</gtr:id><gtr:title>A stepwise advance out of the shadows: leading HIV to its clearance</gtr:title><gtr:parentPublicationTitle>Future Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d25d59a8a6e05b5eff2419f62b6c967"><gtr:id>0d25d59a8a6e05b5eff2419f62b6c967</gtr:id><gtr:otherNames>Hardy G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>585d6c8a109fe6.11225800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0A271EE-883C-4AB8-A9DC-2C6B48BA1BB8</gtr:id><gtr:title>Specificity of anti-human leukocyte antigen antibody responses after immunization with Remune, an inactivated HIV-1 vaccine.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c19689ee331bac7aecb68c4f25c1a58"><gtr:id>6c19689ee331bac7aecb68c4f25c1a58</gtr:id><gtr:otherNames>Page M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>C60815C4429</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F889D81C-904D-4FAE-A109-4EA980B9FECA</gtr:id><gtr:title>Killing of Kaposi's sarcoma-associated herpesvirus-infected fibroblasts during latent infection by activated natural killer cells.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ffcb45a8db974855232fa10b40b227e"><gtr:id>2ffcb45a8db974855232fa10b40b227e</gtr:id><gtr:otherNames>Matthews NC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>Snc3HyUofw5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8248BE60-09EF-4270-BB7D-29C68BF30534</gtr:id><gtr:title>CD34-derived human Langerhans cells stimulate a T helper type 2 response independently of extracellular-signal-regulated kinase phosphorylation.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc90e0da9879623c732f0fd58f7890c7"><gtr:id>fc90e0da9879623c732f0fd58f7890c7</gtr:id><gtr:otherNames>Duraisingham SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>dQHFUsmjCjm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFE29F1F-83BE-4334-BB50-78289645D050</gtr:id><gtr:title>Transient nature of long-term nonprogression and broad virus-specific proliferative T-cell responses with sustained thymic output in HIV-1 controllers.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f987db5d930428320510421f29a35f30"><gtr:id>f987db5d930428320510421f29a35f30</gtr:id><gtr:otherNames>Westrop SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>CD4CDF2DACF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5F0DB6B-05D1-4DA9-99DA-DF0F669F1C6C</gtr:id><gtr:title>The importance of standardisation of laboratory evaluations in HIV vaccine trials.</gtr:title><gtr:parentPublicationTitle>Microbes and infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/569cdc428e1268fb17125485e2b59cbd"><gtr:id>569cdc428e1268fb17125485e2b59cbd</gtr:id><gtr:otherNames>Gotch F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1286-4579</gtr:issn><gtr:outcomeId>E880F2CF506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55E72E30-24E4-431F-822F-5759DE097BD3</gtr:id><gtr:title>Current strategies to test HIV vaccines</gtr:title><gtr:parentPublicationTitle>CYTOMETRY PART B-CLINICAL CYTOMETRY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28ebcd7e513c26706bf8b094aad37ccb"><gtr:id>28ebcd7e513c26706bf8b094aad37ccb</gtr:id><gtr:otherNames>Gotch F.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1552-4949</gtr:issn><gtr:outcomeId>E17109F176D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5523ACBA-945A-430C-ABCD-D553665273FA</gtr:id><gtr:title>T-cell signalling in antiretroviral-treated, aviraemic HIV-1-positive individuals is present in a raised state of basal activation that contributes to T-cell hyporesponsiveness.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7de7ce7b46ffa6f982ac3ddce3ec0d6"><gtr:id>e7de7ce7b46ffa6f982ac3ddce3ec0d6</gtr:id><gtr:otherNames>Downey JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>K6XkdLQUKq6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A9788BC-19C5-4CF3-A943-B2F7030892C5</gtr:id><gtr:title>Restoration of anti-tetanus toxoid responses in patients initiating highly active antiretroviral therapy with or without a boost immunization: an INITIO substudy.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8b699e4e78b665e39d0530646ba489f"><gtr:id>d8b699e4e78b665e39d0530646ba489f</gtr:id><gtr:otherNames>Burton CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>F01FC4A65C0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7950CFE2-7427-476A-98E0-63BB4450FAD0</gtr:id><gtr:title>Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d059dbc4914f17c37d7d722fd0a62d15"><gtr:id>d059dbc4914f17c37d7d722fd0a62d15</gtr:id><gtr:otherNames>Rosignoli G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>2BC5A2213BC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8D7DFF8-F80E-4008-BC3C-4B5320FAB5E5</gtr:id><gtr:title>HIV-1 clade A infection and viral control: an immunological perspective on a case of underquantification.</gtr:title><gtr:parentPublicationTitle>International journal of STD &amp; AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f987db5d930428320510421f29a35f30"><gtr:id>f987db5d930428320510421f29a35f30</gtr:id><gtr:otherNames>Westrop SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0956-4624</gtr:issn><gtr:outcomeId>doi_55f983983ca40274</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDDC1CA5-362A-451E-B6FD-8B621BDF2672</gtr:id><gtr:title>Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010.</gtr:title><gtr:parentPublicationTitle>Journal of translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3817427e64f1158c1126bfcb3ce22bda"><gtr:id>3817427e64f1158c1126bfcb3ce22bda</gtr:id><gtr:otherNames>Brinckmann S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1479-5876</gtr:issn><gtr:outcomeId>CC1HcWCJC5m</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C066EDBE-EC71-4221-8A89-55AB00CE8558</gtr:id><gtr:title>Reduced T(H)1/T(H)17 CD4 T-cell numbers are associated with impaired purified protein derivative-specific cytokine responses in patients with HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e35346ca0059a858cb4a8e9b2d9c82b"><gtr:id>7e35346ca0059a858cb4a8e9b2d9c82b</gtr:id><gtr:otherNames>Clark S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>KjvbtczHMRZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>408B6DB6-232C-412E-9234-7A57ACE360F3</gtr:id><gtr:title>Recent HIV-1 infection in a high-risk Ugandan cohort: implications for Phase IIB test-of-concept HIV vaccine trials.</gtr:title><gtr:parentPublicationTitle>Pharmacogenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72636c570e195a2e1f665711952b6f6b"><gtr:id>72636c570e195a2e1f665711952b6f6b</gtr:id><gtr:otherNames>Kebba A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1462-2416</gtr:issn><gtr:outcomeId>54874A13348</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD035DAC-D9E3-42EC-BB97-54224601ECCC</gtr:id><gtr:title>Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV cohort, 1988-2010.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66c7aad037565da9effe9901fc8d5445"><gtr:id>66c7aad037565da9effe9901fc8d5445</gtr:id><gtr:otherNames>Mandalia S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13685_25_22363409</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F2CFC22-F7D8-4D8B-82B9-58B4F27E32B0</gtr:id><gtr:title>Science, medicine and research in the developing world: a perspective.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/569cdc428e1268fb17125485e2b59cbd"><gtr:id>569cdc428e1268fb17125485e2b59cbd</gtr:id><gtr:otherNames>Gotch F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>526955A1EB9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D37F24A6-1DAC-4417-9142-EC445C4B3E58</gtr:id><gtr:title>TLR-stimulated CD34 stem cell-derived human skin-like and monocyte-derived dendritic cells fail to induce Th17 polarization of naive T cells but do stimulate Th1 and Th17 memory responses.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc90e0da9879623c732f0fd58f7890c7"><gtr:id>fc90e0da9879623c732f0fd58f7890c7</gtr:id><gtr:otherNames>Duraisingham SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>DB68CABD973</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97A91F71-6D7A-4A18-B8C8-D253F234D07D</gtr:id><gtr:title>Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b709ad3b8e7698295cad3772f08cf235"><gtr:id>b709ad3b8e7698295cad3772f08cf235</gtr:id><gtr:otherNames>Guimar?es-Walker A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>080B417E4F7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3D1ABF4-3145-40D6-B3D3-5EDDCCFDC51F</gtr:id><gtr:title>Profile of T cell recognition of HIV type 1 consensus group M Gag and Nef peptides in a clade A1- and D-infected Ugandan population.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40c4ac075a6de4679b80ef146ceae513"><gtr:id>40c4ac075a6de4679b80ef146ceae513</gtr:id><gtr:otherNames>Serwanga J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>oQG6e9RgXoN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94BC7119-DA08-4BE8-949C-7BBDD9EA3FDE</gtr:id><gtr:title>Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8b699e4e78b665e39d0530646ba489f"><gtr:id>d8b699e4e78b665e39d0530646ba489f</gtr:id><gtr:otherNames>Burton CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>76DEB62B4C2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3359849-EA2D-49C2-A6DF-F5659547E916</gtr:id><gtr:title>Gene expression profiling in male genital lichen sclerosus.</gtr:title><gtr:parentPublicationTitle>International journal of experimental pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd0ddc10e399f1643379c06a1af1b820"><gtr:id>bd0ddc10e399f1643379c06a1af1b820</gtr:id><gtr:otherNames>Edmonds E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0959-9673</gtr:issn><gtr:outcomeId>ZJSzgWLqBBP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BA458D8-1738-419F-A125-9CDA5F3B6D3B</gtr:id><gtr:title>Therapeutic vaccines and immunotherapy revisited.</gtr:title><gtr:parentPublicationTitle>Journal of HIV therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/569cdc428e1268fb17125485e2b59cbd"><gtr:id>569cdc428e1268fb17125485e2b59cbd</gtr:id><gtr:otherNames>Gotch F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1462-0308</gtr:issn><gtr:outcomeId>F4097671B8C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96292FB4-C1A7-46E7-AC2A-D2E9CDA7567C</gtr:id><gtr:title>CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>Molecular medicine (Cambridge, Mass.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f987db5d930428320510421f29a35f30"><gtr:id>f987db5d930428320510421f29a35f30</gtr:id><gtr:otherNames>Westrop SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1076-1551</gtr:issn><gtr:outcomeId>pm_13685_25_22875102</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2709181E-F798-442F-90F7-41DC0CB56885</gtr:id><gtr:title>miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71c13663cd7f25b4656bcd671aa8c3a7"><gtr:id>71c13663cd7f25b4656bcd671aa8c3a7</gtr:id><gtr:otherNames>Lagos D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn><gtr:outcomeId>onhwt5ZGD5P</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>102C0268-724B-4459-BC4F-47A98DF6C61E</gtr:id><gtr:title>Loss of NK stimulatory capacity by plasmacytoid and monocyte-derived DC but not myeloid DC in HIV-1 infected patients.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8b31587f34c13d4d8e683294e95790d"><gtr:id>d8b31587f34c13d4d8e683294e95790d</gtr:id><gtr:otherNames>Benlahrech A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>QFTnESAbZnr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EB3CE8D-B8B9-470A-B3E9-6BAD3545A012</gtr:id><gtr:title>The CD8 and CD4 T-cell response against Kaposi's sarcoma-associated herpesvirus is skewed towards early and late lytic antigens.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0988cb57bc8067ff3f49d02de14bc7bd"><gtr:id>0988cb57bc8067ff3f49d02de14bc7bd</gtr:id><gtr:otherNames>Robey RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>JdJ7RxK6QW5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DD00F15-FC7D-458A-95BA-70D4659491E4</gtr:id><gtr:title>Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapy.</gtr:title><gtr:parentPublicationTitle>Journal of immune based therapies and vaccines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe01c9d9af69785d162bec7701d31549"><gtr:id>fe01c9d9af69785d162bec7701d31549</gtr:id><gtr:otherNames>Pires A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1476-8518</gtr:issn><gtr:outcomeId>343124BDE81</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>992D649E-AA50-485B-8D67-1FE2429ED70D</gtr:id><gtr:title>Enrichment of HLA Types and Single-Nucleotide Polymorphism Associated With Non-progression in a Strictly Defined Cohort of HIV-1 Controllers.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f987db5d930428320510421f29a35f30"><gtr:id>f987db5d930428320510421f29a35f30</gtr:id><gtr:otherNames>Westrop SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a361c170dbb69.80092934</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C777089-27AB-4B02-B066-922BFE344EE9</gtr:id><gtr:title>HIV/AIDS cohorts in Uganda. An interview with Frances Gotch.</gtr:title><gtr:parentPublicationTitle>IAVI report : newsletter on international AIDS vaccine research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/569cdc428e1268fb17125485e2b59cbd"><gtr:id>569cdc428e1268fb17125485e2b59cbd</gtr:id><gtr:otherNames>Gotch F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1816-6253</gtr:issn><gtr:outcomeId>C23C5AA2C6B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A7E6717-2C83-401C-A9DD-389CAE1BB500</gtr:id><gtr:title>Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/061c5ff74b27c1b3aee93f0db302e4ec"><gtr:id>061c5ff74b27c1b3aee93f0db302e4ec</gtr:id><gtr:otherNames>Spentzou A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>YyFCm4eBxbq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7EF4E562-DAA3-430C-803B-F502EEEFEBF1</gtr:id><gtr:title>Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8b31587f34c13d4d8e683294e95790d"><gtr:id>d8b31587f34c13d4d8e683294e95790d</gtr:id><gtr:otherNames>Benlahrech A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>9D5F0A3730E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E0B173F-76A6-4D17-9367-E2911B709A97</gtr:id><gtr:title>Elevated plasma lipopolysaccharide is not sufficient to drive natural killer cell activation in HIV-1-infected individuals.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f062a92b9e5ac31dfe716b778a109700"><gtr:id>f062a92b9e5ac31dfe716b778a109700</gtr:id><gtr:otherNames>Gregson JN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>69AD7F37DC8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E091CEAF-5D94-4DBE-B4F6-821F217B321E</gtr:id><gtr:title>Human papillomavirus in the era of highly active antiretroviral therapy for human immunodeficiency virus: an immune reconstitution-associated disease?</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3b31c9cc92ded6ab677df554f2dc341"><gtr:id>c3b31c9cc92ded6ab677df554f2dc341</gtr:id><gtr:otherNames>Meys R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>FQDbhkqUbfX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13E5EE46-C42C-4F79-AF5E-D441C57ADDBF</gtr:id><gtr:title>Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/981d83fb83f38414d9549c4eeed94187"><gtr:id>981d83fb83f38414d9549c4eeed94187</gtr:id><gtr:otherNames>Gudmundsdotter L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>ZjzscBnX3fY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FBA8E84-B9FD-4AD9-8123-FE09D75A8589</gtr:id><gtr:title>Multifarious immunotherapeutic approaches to cure HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>Human vaccines &amp; immunotherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e086ef237c69f5d7e2326de60af7d86a"><gtr:id>e086ef237c69f5d7e2326de60af7d86a</gtr:id><gtr:otherNames>Imami N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2164-5515</gtr:issn><gtr:outcomeId>5675e5f7da8de</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7EA3B2D5-A3F9-4066-9D24-C0A8A422ADC0</gtr:id><gtr:title>Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: lack of reversion with highly active antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e4da6d0f3533ad6c61766067786835b"><gtr:id>8e4da6d0f3533ad6c61766067786835b</gtr:id><gtr:otherNames>Mela CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>C4E4BBFEE00</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D900841-9FAA-4291-AE3D-9E5046D4A1E1</gtr:id><gtr:title>Long-term increase of CD4+ central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunization.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/981d83fb83f38414d9549c4eeed94187"><gtr:id>981d83fb83f38414d9549c4eeed94187</gtr:id><gtr:otherNames>Gudmundsdotter L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>DCB3487B1E2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED7096FD-E8B0-4355-AD01-55C960949FBA</gtr:id><gtr:title>A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Journal of immune based therapies and vaccines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/343ad531546cd309e16b6dc410f86821"><gtr:id>343ad531546cd309e16b6dc410f86821</gtr:id><gtr:otherNames>Hardy GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1476-8518</gtr:issn><gtr:outcomeId>CAE1140594E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64BF41E2-716B-44AD-9F38-335084928EB1</gtr:id><gtr:title>Altered phenotype of regulatory T cells associated with lack of human immunodeficiency virus (HIV)-1-specific suppressive function.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8b699e4e78b665e39d0530646ba489f"><gtr:id>d8b699e4e78b665e39d0530646ba489f</gtr:id><gtr:otherNames>Burton CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>pm_13685_25_21985365</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>800A2C26-BC68-4434-ABA8-313832435A06</gtr:id><gtr:title>Low-dose growth hormone for 40 weeks induces HIV-1-specific T cell responses in patients on effective combination anti-retroviral therapy.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00df1243104040a0c4416ecb9ffb8dc1"><gtr:id>00df1243104040a0c4416ecb9ffb8dc1</gtr:id><gtr:otherNames>Herasimtschuk AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>pm_540e148e148661fa7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54424FE7-5545-43DD-9C2E-E008C22D2122</gtr:id><gtr:title>Host HLA B*allele-associated multi-clade Gag T-cell recognition correlates with slow HIV-1 disease progression in antiretroviral therapy-na&amp;iuml;ve Ugandans.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40c4ac075a6de4679b80ef146ceae513"><gtr:id>40c4ac075a6de4679b80ef146ceae513</gtr:id><gtr:otherNames>Serwanga J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>1ABF4E717DE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>967B9F1B-C1A7-4566-ADC4-C51BA0FCAFE6</gtr:id><gtr:title>Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e818b9a018ceb6c62a51d7a5f557025c"><gtr:id>e818b9a018ceb6c62a51d7a5f557025c</gtr:id><gtr:otherNames>Herasimtschuk A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>doi_55f983983c9181da</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9695347A-8F01-451B-833E-94C5BDD83EFF</gtr:id><gtr:title>CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells &amp;lt;200 Cell/?L: The DART Trial STI Substudy.</gtr:title><gtr:parentPublicationTitle>AIDS research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40c4ac075a6de4679b80ef146ceae513"><gtr:id>40c4ac075a6de4679b80ef146ceae513</gtr:id><gtr:otherNames>Serwanga J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2090-1240</gtr:issn><gtr:outcomeId>eZQ25KucKEE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2801EC30-59C4-4F1C-A0AF-15039A2318FE</gtr:id><gtr:title>Three-year immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 disease.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6589a6edec43e949cf7efb511a358e84"><gtr:id>6589a6edec43e949cf7efb511a358e84</gtr:id><gtr:otherNames>Samri A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>2932232271A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EACC6429-5274-4169-9F45-29C52ECBDFCA</gtr:id><gtr:title>Measuring human T cell responses in blood and gut samples using qualified methods suitable for evaluation of HIV vaccine candidates in clinical trials.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b08a81488a47ee697f1a887b2a6ed1ed"><gtr:id>b08a81488a47ee697f1a887b2a6ed1ed</gtr:id><gtr:otherNames>Kaltsidis H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>LLaQ4VAfSBo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1888BE7-686F-48CA-8F90-06F8103662F0</gtr:id><gtr:title>Expression of PD-L1, a marker of disease status, is not reduced by HAART in aviraemic patients.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d059dbc4914f17c37d7d722fd0a62d15"><gtr:id>d059dbc4914f17c37d7d722fd0a62d15</gtr:id><gtr:otherNames>Rosignoli G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>2ED42159936</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501957</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>